Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. (NASDAQ: VERU) is a late clinical-stage biopharmaceutical company advancing innovative therapies for cardiometabolic diseases, oncology, acute respiratory distress syndrome (ARDS), and sexual health. This page provides investors and stakeholders with timely updates on clinical trial progress, regulatory milestones, and strategic initiatives.
Access the latest Veru news, including press releases on drug development programs like enobosarm for muscle preservation during weight loss and sabizabulin for inflammatory conditions. Stay informed about earnings updates, partnership announcements, and scientific advancements across Veru's diversified pipeline.
All content is sourced directly from company communications and vetted financial news outlets. Bookmark this page for streamlined access to critical updates affecting Veru investment analysis and market positioning.
Veru Inc. (NASDAQ: VERU) announced its participation in the World Obesity and Weight Management Congress, scheduled for October 24-26, 2024, in Baltimore, Maryland. The company will deliver a keynote presentation on October 25, 2024, from 9:40 AM to 10:20 AM EDT at the Best Western Plus Hotel & Conference Center.
The presentation, titled 'Advancing enobosarm, an oral novel Selective Androgen Receptor Modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) drugs for potentially higher quality weight loss', will focus on the scientific support for combining enobosarm with GLP-1 receptor agonists to preserve muscle during weight loss.
Veru Inc. is a late clinical stage biopharmaceutical company developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome.
Veru Inc. (NASDAQ: VERU), a late-stage biopharmaceutical company, will present at the 2024 Cantor Global Healthcare Conference on September 18th at 1:55 PM Eastern Time. Dr. Mitchell Steiner, the company's Chairman, President, and CEO, will provide a corporate update focusing on Veru's Phase 2b clinical development program of enobosarm.
The presentation will highlight enobosarm's potential to enhance fat loss and prevent muscle loss when used in combination with GLP-1 drugs for weight loss. This aligns with Veru's mission to develop innovative medicines for preserving muscle in high-quality weight loss, oncology, and viral-induced acute respiratory distress syndrome.
Investors can access a live webcast of the presentation through Veru's website, with an archived version available afterward.
Veru Inc. (NASDAQ: VERU) has reached full enrollment of over 150 patients for its Phase 2b QUALITY clinical study of enobosarm in combination with semaglutide (Wegovy®) for obesity. The study aims to evaluate enobosarm's efficacy in preserving muscle mass and enhancing fat loss in patients using GLP-1 drugs for weight management. Topline data for the primary endpoint of lean body mass is expected in January 2025.
Financial highlights for Q3 FY2024 include:
- Net revenues increased to $4.0 million from $3.3 million
- Gross profit increased to $1.3 million from $1.2 million
- Research and development expenses decreased to $4.9 million from $8.8 million
- Net loss was $11.0 million, or $0.07 per share, compared to $12.5 million, or $0.14 per share
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced it will host a conference call and audio webcast on August 8, 2024, at 8:00 a.m. ET to discuss its fiscal 2024 third quarter financial results and provide a business update. The company focuses on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome.
Investors can access the audio webcast on Veru's website under the Investors page. To join the conference call, participants can dial 1-800-341-1602 (domestic) or 1-412-902-6706 (international). An archived version of the webcast will be available for replay on the company's website for approximately three months, and a telephonic replay will be accessible for one week.
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company, has announced its participation in the BTIG Virtual Biotechnology Conference on August 5th, 2024. The company will engage in one-on-one meetings with investors during the event.
Veru specializes in developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome. This conference participation provides an opportunity for Veru to connect with potential investors and showcase its latest developments in these critical areas of medical research.
The virtual format of the conference aligns with the ongoing trend of digital interactions in the biotechnology sector, allowing for efficient and widespread engagement with the investment community.
Veru (NASDAQ: VERU), a late clinical stage biopharmaceutical company, announced its participation in the Leerink Therapeutics Forum: I&I and Metabolism on July 9th, 2024, in Boston, Massachusetts. Veru is focused on developing innovative medicines for muscle preservation, weight loss, oncology, and viral-induced acute respiratory distress syndrome. The company aims to leverage this platform to showcase its latest developments and clinical progress. This participation underscores Veru's commitment to advancing therapeutic solutions in its core areas of focus.
Veru announced data from two late-breaking presentations at the American Diabetes Association's 84th Scientific Sessions held June 21-24, 2024, in Orlando, Florida. The presentations highlighted the safety and efficacy of enobosarm, a drug aimed at muscle preservation and high-quality weight loss. A pooled safety analysis (Poster #2067-LB) involving 1,027 subjects indicated that enobosarm was well-tolerated with similar adverse event rates to placebo, though elevated ALT levels were noted in 3.7% of enobosarm subjects versus 1.4% for placebo. A meta-analysis (Poster #2066-LB) involving 367 subjects showed enobosarm reduced fat mass by 6.26% and increased lean mass by 4.04% over placebo, suggesting its potential to improve weight loss quality.
Veru Inc. (NASDAQ: VERU) has adjourned its 2024 Annual Shareholders Meeting, initially scheduled for June 18, 2024, to June 27, 2024, due to a lack of quorum. The meeting was convened without any business conducted as only 49.6% of shareholders' proxies were submitted, short of the required majority. Shareholders who previously voted do not need to take any further action; their votes will be counted in the rescheduled meeting unless revoked. The record date remains April 29, 2024. Shareholders are encouraged to vote to avoid additional costs.
Veru, a late clinical-stage biopharmaceutical company listed on NASDAQ under the symbol VERU, reminds shareholders to vote ahead of its 2024 Annual Meeting of Shareholders. The meeting is set for June 18, 2024, at 9:00 AM ET. Shareholders should submit their votes before the proxy voting deadline, which is also on June 18, 2024, at 9:00 AM ET. Voting can be done online or via telephone based on instructions in the Form of Proxy or Voting Instruction Form. Detailed materials are available on the company’s website.
Veru, a clinical stage biopharmaceutical company (NASDAQ: VERU), will present at the American Diabetes Association's 84th Scientific Sessions from June 21-24, 2024, in Orlando, Florida.
The company will showcase two presentations on June 22, 2024:
1. A pooled safety analysis of Enobosarm from Phase 2 and Phase 3 placebo-controlled clinical trials.
2. A meta-analysis of body composition from three randomized clinical trials, highlighting Enobosarm’s ability to preserve muscle while reducing fat.
Both presentations are scheduled from 12:30 PM to 01:30 PM EDT at the West Concourse A4-B2.
